Organization (Academic)
Loma Linda University
ClinicalTrials.gov lists Loma Linda University as lead sponsor of 305 trials. It has 51 active development programs and 56 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 21 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 18 in 2026 and about 13 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 21 already registered with a 2026 start date: at the cutoff, 6 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
This page covers Loma Linda University: 305 lead-sponsored trials and 1 legal-entity registration.
Disease areas (230)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 34 |
| Diabetes Mellitus | 15 |
| Inflammation | 12 |
| Obesity | 11 |
| Postoperative Pain | 10 |
Showing 5 of 230 disease areas.
Trials by start year as sponsor or collaborator (27)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 21 |
| 2025 | 7 |
| 2024 | 17 |
| 2023 | 20 |
| 2022 | 18 |
| 2021 | 18 |
| 2020 | 18 |
| 2019 | 22 |
| 2018 | 25 |
| 2017 | 20 |
Showing 10 of 27 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 17 trials still running at the 2026-10-09 snapshot; 10 of 17 predicted trials reach the 36-month horizon; registered median of 19 months across 220 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (51)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Toothpaste Tablet | Gingivitis | Phase 3 | 2 |
| Conventional Toothpaste | Gingivitis | Phase 3 | 2 |
| Oral Labetalol | Hypertension | Phase 3 | 1 |
| Conventional Toothpaste | Dental Caries | Phase 3 | 1 |
| Oral Nifedipine | Hypertension | Phase 3 | 1 |
Showing 5 of 51 active programs.
Approved assets (56)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Corticosteroid (celestone) injection | 3 |
| +/- Bupivacaine HCl | 3 |
| Prednisone | 2 |
| Omeprazole | 1 |
| Hydrogen Peroxide Gel, 13 weeks | 1 |
Showing 5 of 56 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 21% hit target (n=142) | 44% on time (n=125) |
Journals published in (532)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Clinical oral implants research | 19 |
| Anesthesia and analgesia | 18 |
| American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons | 15 |
| Journal of clinical periodontology | 15 |
| The New England journal of medicine | 12 |
Showing 5 of 532 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 71 | 11 | 2025-04-15 |
Financing and grant events (116)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-12 | NIH grant | 679,280 | Reporter |
| 2025-09-11 | NIH grant | 358,823 | Reporter |
| 2025-08-08 | NIH grant | 475,001 | Reporter |
| 2025-07-24 | NIH grant | 173,016 | Reporter |
| 2025-07-14 | NIH grant | 727,669 | Reporter |
Showing 5 of 116 events.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2005-01-24 |
Organization relationships (34)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| The Cleveland Clinic | Co sponsors trial with | 3 |
| Government of the United States of America | Co sponsors trial with | 3 |
| University of California System | Co sponsors trial with | 2 |
| Sharp Mary Birch Hospital for Women & Newborns | Co sponsors trial with | 2 |
| Sharp HealthCare | Co sponsors trial with | 2 |
Showing 5 of 34 relationships.
Latest dated events (526)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 526 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| LOMA LINDA UNIVERSITY | Certificate of accreditation | Active |
| LOMA LINDA UNIVERSITY | Certificate of accreditation | Active |
| LOMA LINDA UNIVERSITY | Certificate of waiver | Terminated |
Biomarker capability evidence (93)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACAT1 | Trial sponsor | Named in trial inclusion criteria |
| ADCY10 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| APOBEC3C | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 93 evidence rows.
Biomarkers this organization publishes on (192)
Shown in this order: most publications first.
Showing 5 of 192 biomarkers.
On Scientist.com
Loma Linda University is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.
Work with Loma Linda University on Scientist.com
For prices, more details, or to contact Loma Linda University, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.